Non-Invasive, Painless, Accurate.
- - The DDx - -   
A tool for dramatically improved diagnoses of skin cancer in the doctor’s office or clinic

HomeThe DDx ProductTechnologyFor Patients About/Contact

Melanoma, Squamous Cell Carcinoma (SCC), Basal Cell Carcinoma (BCC) – Skin cancer is the most common kind of cancer. In the US it outnumbers all other cancers together. Melanoma and SCC kill. BCC, the single most common cancer of all, can disfigure.

According to the American Cancer Society, melanoma patients’ overall 5-year survival rate is 98% if their melanoma is detected early. Later, after the tumor has spread to regional lymph nodes or other organs, the survival rate falls to 62%. If the cancer is neglected long enough that it metastasizes to distant organs, the survival rate drops to 15%.

Many in-clinic diagnoses of skin cancer may miss small early stage cancers, including melanoma. Early stage melanomas have a higher cure rate than late stage melanoma, which is very deadly. Indeed, higher accuracy is needed for both larger lesions and smaller ones to improve melanoma survival. This will save lives. Currently, because doctors want to protect their patients, they surgically remove and biopsy many suspect lesions that turn out to be benign. In fact, only about 1 in 20 biopsies for melanoma actually turn out to be melanoma. This causes patients unnecessary pain and anxiety, and costs the health care system an estimated $2 billion a year in the US alone.   Learn more ... 
The DDx enables greatly improved in-clinic diagnoses of skin cancer. 
Early Detection saves lives….
Using the DDx, doctors can achieve far more accurate diagnoses of skin cancer than possible today. For most patients immediate answers will be available right in the office or clinic. Early clinical studies indicate that with the DDx melanoma can be diagnosed with near perfect accuracy, and the other major skin cancers with greatly improved accuracy compared to today’s clinical results. The DDx can also evaluate very small lesions before they have developed the visible features that an expert doctor uses to identify them as cancer.

The DDX is a novel point of care device capable of rapid, accurate, non-invasive skin-cancer diagnosis in a doctor’s clinic. It features a novel, proprietary hand-held “light wand,” using cutting edge fiber-optic technology.  

The end of the DDX “light wand” is touched to the suspect lesion, and in less than five seconds three non-invasive painless optical measurements are made, quickly evaluating suspect lesions. Within a few seconds the resulting evaluation of the lesion is available to the clinical staff. Each of the three optical measurements evaluates a different set of biological markers for skin cancer. This greatly increases diagnostic accuracy compared to any single measurement. The DDx has been shown to be much more accurate than visual inspection by expert doctors -- and also much better than other known technological solutions.  Learn more ...

     DermDx, Inc.
DDx is not yet approved for sale in Europe and US.